Chronic lymphocytic leukemia and myeloproliferative neoplasms concurrently diagnosed: clinical and biological characteristics

References

• Call TG, Phyliky RL, Noel P, et al. Incidence of chronic lymphocytic leukemia in Olmsted County, Minnesota, 1935 through 1989, with emphasis on changes in initial stage at diagnosis. Mayo Clinic Proc 1994; 69: 323–328.
   PubMed Web of Science ®Google Scholar
• Mehta J, Wang H, Iqbal SU, et al. Epidemiology of myeloproliferative neoplasms in the United States. Leuk Lymphoma 2014; 55: 595–600.
   PubMed Web of Science ®Google Scholar
• Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clinicians 2014; 64: 9–29.
   PubMed Web of Science ®Google Scholar
• Kodali S, Chen C, Rathnasabapathy C, et al. JAK2 mutation in a patient with CLL with coexistent myeloproliferative neoplasm (MPN). Leuk Res 2009; 33: e236–e239.
   PubMedGoogle Scholar
• Salama ME, Swierczek SI, Tashi T, et al. Calreticulin mutated prefibrotic-stage myelofibrosis and PMF represent an independent clone from coexisting CLL. Blood 2014; 124: 1691–1692.
   PubMed Web of Science ®Google Scholar
• Swierczek S, Nausova J, Jelinek J, et al. Concomitant JAK2 V617F-positive polycythemia vera and B-cell chronic lymphocytic leukemia in three patients originating from two separate hematopoietic stem cells. Am J Hematol 2013; 88: 157–158.
   PubMed Web of Science ®Google Scholar
• Kim H, Jang W, Shin S, et al. Two cases of concurrent development of essential thrombocythemia with chronic lymphocytic leukemia, one related to clonal B-cell lymphocytosis, tested by array comparative genomic hybridization. Int J Hematol 2014. [Epub ahead of print]. doi: 10.1007/s12185-014-1713-9.
   Web of Science ®Google Scholar
• Laurenti L, Tarnani M, Nichele I, et al. The coexistence of chronic lymphocytic leukemia and myeloproliperative neoplasms: a retrospective multicentric GIMEMA experience. Am J Hematol 2011; 86: 1007–1012.
   PubMed Web of Science ®Google Scholar
• Fianchi L, Pagano L, Piciocchi A, et al. Characteristics and outcome of therapy-related myeloid neoplasms: report from the Italian network on secondary leukemias. Am J Hematol 2015; 90: E80–E85.
   PubMed Web of Science ®Google Scholar
• Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010; 115: 1703–1708.
   PubMed Web of Science ®Google Scholar
• Rumi E, Passamonti F, Elena C, et al. Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients. Haematologica 2011; 96: 454–458.
   PubMed Web of Science ®Google Scholar
• Bryder D, Rossi DJ, Weissman IL. Hematopoietic stem cells: the paradigmatic tissue-specific stem cell. Am J Pathol 2006; 169: 338–346.
   PubMed Web of Science ®Google Scholar
• Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. New Eng J Medicine 2013; 369: 2379–2390.
   PubMed Web of Science ®Google Scholar
• Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. New Eng J Medicine 2013; 369: 2391–2405.
   PubMed Web of Science ®Google Scholar
• Puente XS, Pinyol M, Quesada V, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011; 475: 101–105.
   PubMed Web of Science ®Google Scholar
• Quesada V, Conde L, Villamor N, et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nature Genet 2012; 44: 47–52.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris NL, et al. World Health Organization classification of tumours of hematopoietic and lymphoid tissues. 4th ed. Lyon, France: IARC Press; 2008.
   Google Scholar
• Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111: 5446–5456.
   PubMed Web of Science ®Google Scholar
• Nussenzveig RH, Swierczek SI, Jelinek J, et al. Polycythemia vera is not initiated by JAK2V617F mutation. Experim Hematol 2007; 35: 32–38.
   PubMed Web of Science ®Google Scholar
• Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009; 113: 2895–2901.
   PubMed Web of Science ®Google Scholar
• Wierda WG, O’Brien S, Wang X, et al. Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia. J Clinical Oncol 2011; 29: 4088–4095.
   PubMed Web of Science ®Google Scholar
• Tadmor T, Shvidel L, Aviv A, et al. Significance of bone marrow reticulin fibrosis in chronic lymphocytic leukemia at diagnosis: a study of 176 patients with prognostic implications. Cancer 2013; 119: 1853–1859.
   PubMed Web of Science ®Google Scholar
• Passamonti F, Thiele J, Girodon F, et al. A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment. Blood 2012; 120: 1197–1201.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Rumi E, Finazzi G, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia 2013; 27: 1874–1881.
   PubMed Web of Science ®Google Scholar
• Tefferi A. Myelofibrosis with myeloid metaplasia. New Eng J Medicine 2000; 342: 1255–1265.
   PubMed Web of Science ®Google Scholar
• Pflug N, Bahlo J, Shanafelt TD, et al. Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. Blood 2014; 124: 49–62.
   PubMed Web of Science ®Google Scholar
• Adams AM, Hudson RR. Maximum-likelihood estimation of demographic parameters using the frequency spectrum of unlinked single-nucleotide polymorphisms. Genetics 2004; 168: 1699–1712.
   PubMed Web of Science ®Google Scholar
• Tomasetti C, Vogelstein B. Cancer etiology. Variation in cancer risk among tissues can be explained by the number of stem cell divisions. Science (NY) 2015; 347: 78–81.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646–674.
   PubMed Web of Science ®Google Scholar
• Damm F, Mylonas E, Cosson A, et al. Acquired initiating mutations in early hematopoietic cells of CLL patients. Cancer Discovery 2014; 4: 1088–1101.
   PubMed Web of Science ®Google Scholar
• Kikushige Y, Ishikawa F, Miyamoto T, et al. Self-renewing hematopoietic stem cell is the primary target in pathogenesis of human chronic lymphocytic leukemia. Cancer Cell 2011; 20: 246–259.
   PubMed Web of Science ®Google Scholar
• Ylipaa A, Yli-Harja O, Zhang W, et al. Characterization of aberrant pathways across human cancers. BMC Syst Biol 2013; 7(Suppl. 1): S1.
   Google Scholar
• Ortmann CA, Kent DG, Nangalia J, et al. Effect of mutation order on myeloproliferative neoplasms. New Engl J Medicine 2015; 372: 601–612.
   PubMed Web of Science ®Google Scholar
• Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971; 68: 820–823.
   PubMed Web of Science ®Google Scholar
• Rozovski U, Keating MJ, Estrov Z. Targeting inflammatory pathways in chronic lymphocytic leukemia. Crit Rev Oncol/Hematol 2013; 88: 655–666.
   PubMed Web of Science ®Google Scholar
• Barosi G. An immune dysregulation in MPN. Curr Hematolog Malignancy Rep 2014; 9: 331–339.
   PubMed Web of Science ®Google Scholar
• Cervantes F, Hernandez-Boluda JC, Villamor N, et al. Assessment of peripheral blood lymphocyte subsets in idiopathic myelofibrosis. Eur J Haematol 2000; 65: 104–108.
   PubMed Web of Science ®Google Scholar
• Rozovski U, Wu JY, Harris DM, et al. Stimulation of the B-cell receptor activates the JAK2/STAT3 signaling pathway in chronic lymphocytic leukemia cells. Blood 2014; 123: 3797–3802.
   PubMed Web of Science ®Google Scholar
• Oh ST, Simonds EF, Jones C, et al. Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood 2010; 116: 988–992.
   PubMed Web of Science ®Google Scholar
• Teofili L, Martini M, Cenci T, et al. Different STAT-3 and STAT-5 phosphorylation discriminates among Ph-negative chronic myeloproliferative diseases and is independent of the V617F JAK-2 mutation. Blood 2007; 110: 354–359.
   PubMed Web of Science ®Google Scholar